|
 Printer Friendly Version |
Financial TablesHighlights:
|
Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.19 billion for the fourth-quarter ended October 31, 2017, up 7.1 percent year over year (up 5.8 percent on a core basis(2)).
Fourth-quarter GAAP net income was $177 million, or $0.54 per share. Last year's fourth-quarter GAAP net income was $126 million, or $0.38 per share.
During the fourth quarter, Agilent had intangible amortization of $28 million, transformation costs of $7 million and acquisition and integration costs of $5 million. Excluding these items and a tax expense of $1 million, Agilent reported fourth-quarter non-GAAP net income of $218 million, or $0.67 per share(1).
"We ended fiscal 2017 with another strong quarter of revenue and profit growth," said Mike McMullen, Agilent CEO and President. "Every quarter this year we have delivered strong revenue growth, expanded operating margins and increased non-GAAP earnings per share. Our consistently excellent financial performance demonstrates our sustained ability to win in the marketplace, while also driving operational improvements."
"We are successfully executing our strategy positioning Agilent for future growth," he added. "We continue strengthening our portfolio through our own R&D investment and M&A, bringing new capabilities and highly differentiated products to our customers. We have positive momentum heading into fiscal year 2018, and will continue our focus on driving sustainable above-market growth and delivering value to shareholders."
Fourth-quarter revenue of $575 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 5 percent year over year (up 4 percent on a core basis(2)), with strength in chemical and energy, academia and government and food end markets. LSAG's operating margin for the quarter was 23.9 percent.
Fourth-quarter revenue of $404 million from Agilent CrossLab Group (ACG) grew 9 percent year over year (up 8 percent on a core basis(2)). Growth was healthy across services and consumables, most regions and end markets. ACG's operating margin for the quarter was 22.9 percent.
Fourth-quarter revenue of $210 million from Agilent's Diagnostics and Genomics Group (DGG) grew 9 percent year over year (up 7 percent on a core basis(2)) led by increasing demand for pathology products and companion diagnostics services. DGG's operating margin for the quarter was 20.8 percent.
Agilent expects first-quarter 2018 revenue in the range of $1.145 billion to $1.165 billion. First-quarter 2018 non-GAAP earnings are expected to be in the range of $0.55 to $0.57 per share(3).
For fiscal year 2018, Agilent expects revenue of $4.720 billion to $4.740 billion and non-GAAP earnings of $2.50 to $2.56 per share(3). The guidance is based on October 31, 2017, currency exchange rates.
Conference Call
Agilent's management will present more details about its fourth-quarter FY2017 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select "Q4 2017 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events Calendar of Events" section. The webcast will remain available on the company's website for 90 days.
Additional information regarding financial results can be found at www.investor.agilent.com by selecting "Financial Results" in the "Financial Information" section.
A telephone replay of the conference call will be available at approximately 4:30 p.m. PST today through November 27 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 2283927.
# # #
| AGILENT TECHNOLOGIES, INC. | |||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||
| (In millions, except per share amounts) | |||||||||||
| (Unaudited) | |||||||||||
| PRELIMINARY | |||||||||||
| Three Months Ended | |||||||||||
| October 31, | Percent | ||||||||||
| 2017 | 2016 | Inc/(Dec) | |||||||||
| Net revenue | $ | 1,189 | $ | 1,111 | 7 | % | |||||
| Costs and expenses: | |||||||||||
| Cost of products and services | 542 | 523 | 4 | % | |||||||
| Research and development | 89 | 84 | 6 | % | |||||||
| Selling, general and administrative | 325 | 321 | 1 | % | |||||||
| Total costs and expenses | 956 | 928 | 3 | % | |||||||
| Income from operations | 233 | 183 | 27 | % | |||||||
| Interest income | 7 | 3 | 133 | % | |||||||
| Interest expense | (20 | ) | (19 | ) | 5 | % | |||||
| Other income (expense), net | 6 | (16 | ) | — | |||||||
| Income before taxes | 226 | 151 | 50 | % | |||||||
| Provision for income taxes | 49 | 25 | 96 | % | |||||||
| Net income | $ | 177 | $ | 126 | 40 | % | |||||
| Net income per share: | |||||||||||
| Basic | $ | 0.55 | $ | 0.39 | |||||||
| Diluted | $ | 0.54 | $ | 0.38 | |||||||
| Weighted average shares used in computing net income per share: | |||||||||||
| Basic | 322 | 324 | |||||||||
| Diluted | 326 | 328 | |||||||||
| Cash dividends declared per common share | $ | 0.132 | $ | 0.115 | |||||||
| The preliminary income statement is estimated based on our current information. | |||||||||||
| Page 1 | |||||||||||
| AGILENT TECHNOLOGIES, INC. | |||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||
| (In millions, except per share amounts) | |||||||||||
| (Unaudited) | |||||||||||
| PRELIMINARY | |||||||||||
| Years Ended | |||||||||||
| October 31, | Percent | ||||||||||
| 2017 | 2016 | Inc/(Dec) | |||||||||
| Net revenue | $ | 4,472 | $ | 4,202 | 6 | % | |||||
| Costs and expenses: | |||||||||||
| Cost of products and services | 2,063 | 2,005 | 3 | % | |||||||
| Research and development | 339 | 329 | 3 | % | |||||||
| Selling, general and administrative | 1,229 | 1,253 | (2 | %) | |||||||
| Total costs and expenses | 3,631 | 3,587 | 1 | % | |||||||
| Income from operations | 841 | 615 | 37 | % | |||||||
| Interest income | 22 | 11 | 100 | % | |||||||
| Interest expense | (79 | ) | (72 | ) | 10 | % | |||||
| Other income (expense), net | 19 | (10 | ) | — | |||||||
| Income before taxes | 803 | 544 | 48 | % | |||||||
| Provision for income taxes | 119 | 82 | 45 | % | |||||||
| Net income | $ | 684 | $ | 462 | 48 | % | |||||
| Net income per share: | |||||||||||
| Basic | $ | 2.12 | $ | 1.42 | |||||||
| Diluted | $ | 2.10 | $ | 1.40 | |||||||
| Weighted average shares used in computing net income per share: | |||||||||||
| Basic | 322 | 326 | |||||||||
| Diluted | 326 | 329 | |||||||||
| Cash dividends declared per common share | $ | 0.528 | $ | 0.460 | |||||||
| The preliminary income statement is estimated based on our current information. | |||||||||||
| Page 2 | |||||||||||
| AGILENT TECHNOLOGIES, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME | ||||||||||||||||
| (In millions) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| PRELIMINARY | ||||||||||||||||
| Three Months Ended | Years Ended |
|||||||||||||||
| October 31, | October 31, |
|||||||||||||||
| 2017 | 2016 | 2017 |
2016 |
|||||||||||||
| Net income | $ | 177 | $ | 126 | $ | 684 | $ | 462 | ||||||||
| Other comprehensive income (loss), net of tax: | ||||||||||||||||
| Unrealized gain (loss) on derivative instruments | 3 | 5 | — | (6 | ) | |||||||||||
| Amounts reclassified into earnings related to derivative instruments | 1 | 3 | (1 | ) | 3 | |||||||||||
| Foreign currency translation | (21 | ) | (49 | ) | 40 | (8 | ) | |||||||||
| Net defined benefit pension cost and post retirement plan costs: | ||||||||||||||||
| Change in actuarial net loss | 84 | (115 | ) | 118 | (86 | ) | ||||||||||
| Change in net prior service benefit | (2 | ) | (2 | ) | (6 | ) | (15 | ) | ||||||||
| Other comprehensive income (loss) | 65 | (158 | ) | 151 | (112 | ) | ||||||||||
| Total comprehensive income (loss) | $ | 242 | $ | (32 | ) | $ | 835 | $ | 350 | |||||||
| The preliminary statement of comprehensive income is estimated based on our current information. | ||||||||||||||||
| Page 3 | ||||||||||||||||
| AGILENT TECHNOLOGIES, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEET | ||||||||
| (In millions, except par value and share amounts) | ||||||||
| (Unaudited) | ||||||||
| PRELIMINARY | ||||||||
| October 31, | October 31, | |||||||
2017 |
2016(a) |
|||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,678 | $ | 2,289 | ||||
| Accounts receivable, net | 724 | 631 | ||||||
| Inventory | 575 | 533 | ||||||
| Other current assets | 192 | 182 | ||||||
| Total current assets | 4,169 | 3,635 | ||||||
| Property, plant and equipment, net | 757 | 639 | ||||||
| Goodwill | 2,607 | 2,517 | ||||||
| Other intangible assets, net | 361 | 416 | ||||||
| Long-term investments | 138 | 135 | ||||||
| Other assets | 397 | 452 | ||||||
| Total assets | $ | 8,429 | $ | 7,794 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 305 | $ | 257 | ||||
| Employee compensation and benefits | 276 | 235 | ||||||
| Deferred revenue | 291 | 269 | ||||||
| Short-term debt | 210 | — | ||||||
| Other accrued liabilities | 181 | 184 | ||||||
| Total current liabilities | 1,263 | 945 | ||||||
| Long-term debt | 1,801 | 1,904 | ||||||
| Retirement and post-retirement benefits | 242 | 360 | ||||||
| Other long-term liabilities | 293 | 339 | ||||||
| Total liabilities | 3,599 | 3,548 | ||||||
| Total Equity: | ||||||||
| Stockholders' equity: | ||||||||
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding |
— | — | ||||||
Common stock; $0.01 par value, 2 billion shares authorized; 322 million shares at October 31, 2017 and 614 million shares at October 31, 2016, issued |
3 | 6 | ||||||
Treasury stock at cost; zero shares at October 31, 2017 and 290 million shares at October 31, 2016 |
— | (10,508 | ) | |||||
| Additional paid-in-capital | 5,301 | 9,159 | ||||||
| (Accumulated deficit) retained earnings | (126 | ) | 6,089 | |||||
| Accumulated other comprehensive loss | (352 | ) | (503 | ) | ||||
| Total stockholders' equity | 4,826 | 4,243 | ||||||
| Non-controlling interest | 4 | 3 | ||||||
| Total equity | 4,830 | 4,246 | ||||||
| Total liabilities and equity | $ | 8,429 | $ | 7,794 | ||||
(a) Includes the impact of the adoption of ASU 2015-15 and reclassification of technology and licenses from third parties from other assets to other intangible assets, net. |
||||||||
|
||||||||
| The preliminary balance sheet is estimated based on our current information. | ||||||||
| Page 4 | ||||||||
| AGILENT TECHNOLOGIES, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||||||||||
| (In millions) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| PRELIMINARY | ||||||||||||||||
| Three Months Ended | Years Ended | |||||||||||||||
| October 31, | October 31, | October 31, | October 31, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income | $ | 177 | $ | 126 | $ | 684 | $ | 462 | ||||||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||||||||||
| Depreciation and amortization | 52 | 56 | 212 | 246 | ||||||||||||
| Share-based compensation | 12 | 11 | 60 | 58 | ||||||||||||
| Excess and obsolete inventory related charges | 5 | 4 | 24 | 20 | ||||||||||||
| Impairment of equity method investment and loans | — | 25 | — | 25 | ||||||||||||
| Other non-cash expenses, net | 2 | 3 | 7 | 19 | ||||||||||||
| Changes in assets and liabilities: | ||||||||||||||||
| Accounts receivable | (52 | ) | (52 | ) | (81 | ) | (33 | ) | ||||||||
| Inventory | (15 | ) | 4 | (61 | ) | (7 | ) | |||||||||
| Accounts payable | (9 | ) | 12 | 2 | (15 | ) | ||||||||||
| Employee compensation and benefits | 49 | 29 | 38 | 15 | ||||||||||||
| Interest rate swap payments | — | (10 | ) | — | (10 | ) | ||||||||||
| Other assets and liabilities | 67 | 26 | 4 | 13 | ||||||||||||
| Net cash provided by operating activities (a) | 288 | 234 | 889 | 793 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Investments in property, plant and equipment | (58 | ) | (52 | ) | (176 | ) | (139 | ) | ||||||||
| Proceeds from sale of investment securities | — | — | — | 1 | ||||||||||||
| Payment to acquire cost method investment | (1 | ) | — | (1 | ) | (80 | ) | |||||||||
| Loan to equity method investment | — | — | — | (3 | ) | |||||||||||
| Change in restricted cash and cash equivalents, net | (1 | ) | — | (1 | ) | 245 | ||||||||||
| Payment in exchange for convertible note | — | — | (1 | ) | (1 | ) | ||||||||||
| Proceeds from divestitures | 1 | — | 2 | — | ||||||||||||
| Acquisition of businesses and intangible assets, net of cash acquired | (1 | ) | (26 | ) | (128 | ) | (261 | ) | ||||||||
| Net cash used in investing activities | (60 | ) | (78 | ) | (305 | ) | (238 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Issuance of common stock under employee stock plans | 8 | 3 | 66 | 62 | ||||||||||||
| Payment of taxes related to net share settlement of equity awards | (1 | ) | — | (14 | ) | (6 | ) | |||||||||
| Payment of dividends | (43 | ) | (38 | ) | (170 | ) | (150 | ) | ||||||||
| Proceeds from debts and credit facility | 57 | — | 400 | 255 | ||||||||||||
| Repayment of debts and credit facility | (127 | ) | (272 | ) | (290 | ) | (292 | ) | ||||||||
| Proceeds from issuance of senior notes | — | 299 | — | 299 | ||||||||||||
| Debt issuance cost | — | (2 | ) | — | (2 | ) | ||||||||||
| Treasury stock repurchases | — | (46 | ) | (194 | ) | (434 | ) | |||||||||
| Net cash used in financing activities | (106 | ) | (56 | ) | (202 | ) | (268 | ) | ||||||||
| Effect of exchange rate movements | (7 | ) | (10 | ) | 7 | (1 | ) | |||||||||
| Net increase in cash and cash equivalents | 115 | 90 | 389 | 286 | ||||||||||||
| Cash and cash equivalents at beginning of period | 2,563 | 2,199 | 2,289 | 2,003 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 2,678 | $ | 2,289 | $ | 2,678 | $ | 2,289 | ||||||||
| (a) Cash payments included in operating activities: | ||||||||||||||||
| Income tax payments, net | $ | 7 | $ | 13 | $ | 63 | $ | 67 | ||||||||
| Interest payments | $ | 13 | $ | 8 | $ | 82 | $ | 73 | ||||||||
| The preliminary cash flow is estimated based on our current information. | ||||||||||||||||
| Page 5 | ||||||||||||||||
| AGILENT TECHNOLOGIES, INC. | ||||||||||||||||||||||||||||||
| NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS | ||||||||||||||||||||||||||||||
| (In millions, except per share amounts) | ||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||
| PRELIMINARY | ||||||||||||||||||||||||||||||
| Three Months Ended | Years Ended | |||||||||||||||||||||||||||||
| October 31, | October 31, | |||||||||||||||||||||||||||||
| 2017 | Diluted |
2016 | Diluted |
2017 | Diluted |
2016 | Diluted |
|||||||||||||||||||||||
| GAAP Net income | $ | 177 | $ | 0.54 | $ | 126 | $ | 0.38 | $ | 684 | $ | 2.10 | $ | 462 | $ | 1.40 | ||||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||||||||||||||||
| Asset impairments | — | — | — | — | — | — | 4 | 0.01 |
||||||||||||||||||||||
| Intangible amortization | 28 | 0.09 | 32 | 0.10 | 117 | 0.36 | 152 | 0.46 | ||||||||||||||||||||||
| Business exit and divestiture costs | — | — | 4 | 0.01 | — | — | 10 | 0.03 | ||||||||||||||||||||||
| Transformational initiatives | 7 | 0.02 | 6 | 0.02 | 12 | 0.04 | 38 | 0.12 | ||||||||||||||||||||||
| Acquisition and integration costs | 5 | 0.02 | 13 | 0.04 | 32 | 0.10 | 41 | 0.12 | ||||||||||||||||||||||
| Impairment of investment and loans | — | — | 25 | 0.08 | — | — | 25 | 0.08 | ||||||||||||||||||||||
| Pension curtailment gain | — | — | — | — | — | — | (15 | ) | (0.05 | ) | ||||||||||||||||||||
| Pension settlement gain | — | — | — | — | (32 | ) | (0.10 | ) | (1 | ) | — | |||||||||||||||||||
| Other | — | — | 1 | — | 5 | 0.02 | 6 | 0.02 | ||||||||||||||||||||||
| Adjustment for taxes (a) | 1 | — | (14 | ) | (0.04 | ) | (50 | ) | (0.16 | ) | (71 | ) | (0.21 | ) | ||||||||||||||||
| Non-GAAP Net income | $ | 218 | $ | 0.67 | $ | 193 | $ | 0.59 | $ | 768 | $ | 2.36 | $ | 651 | $ | 1.98 | ||||||||||||||
| (a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three months and year ended October 31, 2017, management uses a non-GAAP effective tax rate of 18.0% for both periods. In the same periods last year, management used a non-GAAP effective tax rate of 16.8% and 19.0%, respectively. | ||||||||||||||||||||||||||||||
| We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to asset impairments, amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, impairment of investment and loans, pension curtailment gain and pension settlement gain. | ||||||||||||||||||||||||||||||
| Asset impairments include assets that have been written down to their fair value. | ||||||||||||||||||||||||||||||
| Business exit and divestiture costs include costs associated with the exit of the NMR business and other business divestitures. | ||||||||||||||||||||||||||||||
| Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with the post-separation resizing of the IT infrastructure and streamlining of IT system as well as company programs to transform our product lifecycle management (PLM) system and financial systems. | ||||||||||||||||||||||||||||||
| Acquisition and Integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, tax, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs. | ||||||||||||||||||||||||||||||
| Impairment of investment and loans include an investment and the related convertible loans that have been written down to their fair value. | ||||||||||||||||||||||||||||||
| Pension curtailment gain resulted from certain retirement plans benefit reductions. | ||||||||||||||||||||||||||||||
| Pension settlement gain resulted from transfer of the substitutional portion of our Japanese pension plan to the government. | ||||||||||||||||||||||||||||||
| Other includes certain legal costs and settlements in addition to other miscellaneous adjustments. | ||||||||||||||||||||||||||||||
| Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors. | ||||||||||||||||||||||||||||||
| Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance. | ||||||||||||||||||||||||||||||
| Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies. | ||||||||||||||||||||||||||||||
| The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information. | ||||||||||||||||||||||||||||||
| Page 6 | ||||||||||||||||||||||||||||||
| AGILENT TECHNOLOGIES, INC. | ||||||
| SEGMENT INFORMATION | ||||||
| (In millions, except where noted) | ||||||
| (Unaudited) | ||||||
| PRELIMINARY | ||||||
| Life Sciences and Applied Markets Group | ||||||
| Q4'17 | Q4'16 | |||||
| Revenue | $ | 575 | $ | 548 | ||
| Gross Margin, % | 61.0% | 59.4% | ||||
| Income from Operations | $ | 138 | $ | 125 | ||
| Operating margin, % | 23.9% | 22.8% | ||||
| Diagnostics and Genomics Group | ||||||
| Q4'17 | Q4'16 | |||||
| Revenue | $ | 210 | $ | 193 | ||
| Gross Margin, % | 55.2% | 55.4% | ||||
| Income from Operations | $ | 44 | $ | 38 | ||
| Operating margin, % | 20.8% | 19.6% | ||||
| Agilent CrossLab Group | ||||||
| Q4'17 | Q4'16 | |||||
| Revenue | $ | 404 | $ | 370 | ||
| Gross Margin, % | 49.6% | 49.4% | ||||
| Income from Operations | $ | 92 | $ | 84 | ||
| Operating margin, % | 22.9% | 22.7% | ||||
| Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, impairment of investment and loans, pension curtailment gain and pension settlement gain. | ||||||
| Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies. | ||||||
| The preliminary segment information is estimated based on our current information. | ||||||
| Page 7 | ||||||
| AGILENT TECHNOLOGIES, INC. | |||||||||||||||||||||
| RECONCILIATIONS OF REVENUE BY SEGMENT EXCLUDING THE NMR BUSINESS, | |||||||||||||||||||||
| ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE) | |||||||||||||||||||||
| (in millions) | |||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||
| PRELIMINARY | |||||||||||||||||||||
| Year-over-Year | |||||||||||||||||||||
| GAAP | |||||||||||||||||||||
| Year-over-Year | |||||||||||||||||||||
GAAP Revenue by Segment |
Q4'17 | Q4'16 | % Change | ||||||||||||||||||
| Life Sciences and Applied Markets Group | $ | 575 | $ | 548 | 5 | % | |||||||||||||||
| Diagnostics and Genomics Group | 210 | 193 | 9 | % | |||||||||||||||||
| Agilent CrossLab Group | 404 | 370 | 9 | % | |||||||||||||||||
| Agilent | $ | 1,189 | $ | 1,111 | 7 | % | |||||||||||||||
Non-GAAP |
Currency |
Currency-Adjusted (a) |
|||||||||||||||||||
| Year-over-Year | Year-over-Year | ||||||||||||||||||||
Non GAAP Revenue by Segment |
Q4'17 | Q4'16 | % Change | Q4'17 | Q4'17 | Q4'16 | % Change | ||||||||||||||
| Life Sciences and Applied Markets Group | $ | 573 | $ | 547 | 5 | % | $ | 4 | $ | 569 | $ | 547 | 4 | % | |||||||
| Diagnostics and Genomics Group | 208 | 193 | 7 | % | 2 | 206 | 193 | 7 | % | ||||||||||||
| Agilent CrossLab Group | 404 | 370 | 9 | % | 5 | 399 | 370 | 8 | % | ||||||||||||
| Agilent (Core) | $ | 1,185 | $ | 1,110 | 7 | % | $ | 11 | $ | 1,174 | $ | 1,110 | 6 | % | |||||||
| (a) We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business. To determine the impact of currency fluctuations, current period results for entities reporting in currencies other than United States dollars are converted into United States dollars at the actual exchange rate in effect during the respective prior periods. | |||||||||||||||||||||
| The preliminary reconciliation of GAAP revenue adjusted for the NMR business, recent acquisitions and divestitures and impact of currency is estimated based on our current information. | |||||||||||||||||||||
| Page 8 | |||||||||||||||||||||
Download Financial Statements for Fourth-Quarter Fiscal 2017